https://scholars.lib.ntu.edu.tw/handle/123456789/161502
標題: | EGFR inhibitors as the first-line systemic treatment for advanced non-small-cell lung cancer | 作者: | Kao, Hsiang-Fong Lin, Chia-Chi Yang, James Chih-Hsin |
關鍵字: | afatinib;cetuximab;erlotinib;gefitinib;molecular targeted therapies;non-small-cell lung cancer;personalized medicine | 公開日期: | 2013 | 起(迄)頁: | 991-1003 | 來源出版物: | Future Oncology | 摘要: | Drugs that target the EGFR have a major impact on the treatment of advanced non-small-cell lung cancer (NSCLC). EGFR mutations in NSCLC are associated with a dramatic and sustained response to EGFR tyrosine kinase inhibitors (TKIs). This review summarizes the results of randomized trials using EGFR TKIs or EGFR monoclonal antibodies with chemotherapy in the first-line setting, and discusses several unresolved issues regarding the use of the EGFR TKIs as the first-line therapy in advanced NSCLC. |
URI: | http://ntur.lib.ntu.edu.tw//handle/246246/280061 | DOI: | 10.2217/FON.13.56 |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。